Tools · Private company · Cambridge, MA, US
Clear Scientific, Inc.
Track this companyFree. Adds Clear Scientific, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials30 recruiting or active
Pipeline programs6From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline6
- CS-1103Phase 2 · Fentanyl OverdoseClinicalTrials.gov · fetched Nov 12, 2026
- CS-1103Phase 2 · Methamphetamine IntoxicationClinicalTrials.gov · fetched Nov 12, 2026
- FentanylPhase 2 · Fentanyl OverdoseClinicalTrials.gov · fetched Nov 12, 2026
- MethamphetaminePhase 2 · Methamphetamine IntoxicationClinicalTrials.gov · fetched Nov 12, 2026
- Naloxone HydrochloridePhase 2 · Fentanyl OverdoseClinicalTrials.gov · fetched Nov 12, 2026
- CS-1103Phase 1 · Substance Use DisordersClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials3
- A Phase 2 Safety, Tolerability, PK, and Efficacy Study of CS-1103 Following Fentanyl Challenge With Naloxone BlockadePHASE2 · COMPLETED · started May 28, 2026ClinicalTrials.gov NCT07459166 · fetched Nov 12, 2026
- A Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants Receiving a Single Dose of MethamphetaminePHASE2 · COMPLETED · started Feb 5, 2026ClinicalTrials.gov NCT06721494 · fetched Nov 12, 2026
- A Clinical Study to Evaluate the Safety of CS-1103 in Healthy ParticipantsPHASE1 · COMPLETED · started Feb 7, 2024ClinicalTrials.gov NCT06316973 · fetched Nov 12, 2026
NIH awards6
- A Phase 2a clinical study to evaluate the safety and efficacy of CS-1103, a therapeutic agent to treat methamphetamine intoxicationFiscal year 2026 · $3MNIH RePORTER 1U01DA066075-01 · fetched Nov 12, 2026
- A Novel Reversal Agent for Treatment of Overdose from the Combination of Fentanyl and XylazineFiscal year 2025 · $1.5MNIH RePORTER 5R44DA056272-03 · fetched Nov 12, 2026
- Clinical Development of a Therapeutic Agent for Rapid Reversal of Methamphetamine IntoxicationFiscal year 2025 · $3.8MNIH RePORTER 5U01DA058548-03 · fetched Nov 12, 2026
- A Novel Reversal Agent for Treatment of Overdose from the Combination of Fentanyl and XylazineFiscal year 2024 · $1.5MNIH RePORTER 2R44DA056272-02 · fetched Nov 12, 2026
- Clinical Development of a Therapeutic Agent for Rapid Reversal of Methamphetamine IntoxicationFiscal year 2024 · $4.1MNIH RePORTER 5U01DA058548-02 · fetched Nov 12, 2026
- A Therapeutic Agent to Lower the Level of Synthetic Opioids in the BodyFiscal year 2024 · $3.1MNIH RePORTER 5UG3DA059286-02 · fetched Nov 12, 2026